financetom
Business
financetom
/
Business
/
Surviving the IPO fiasco and a pandemic: WeWork management opens up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Surviving the IPO fiasco and a pandemic: WeWork management opens up
Oct 29, 2020 5:38 AM

When WeWork withdrew its much-anticipated $47-billion IPO in September 2019, it saw valuations plummet to less than $8 billion on concerns over an erratic management and mounting losses.

The firm has since undergone an enormous management shake-up and its new team has emphasised the focus on putting the wheels of this once-promising company back on the track amidst a global pandemic.

According to its second quarter earnings, WeWork saw a 9 percent increase in revenue to 882 million dollars (YoY). It halved the burn rate and expects to be cash flow positive by 2021.

Enterprise companies now represent 48 percent of its over 6 lakh memberships and accounted for more than half of WeWork's core sales for the first time in Q2 2020.

So while the company is confident of a recovery, the street is not convinced yet -- rating agency Fitch downgraded the co-working giant's rating regarding its ability to pay long-term debt to CCC - indicating 'substantial credit risk' where 'default is a real possibility'.

In a scenario where demand is structurally lower, Fitch sees WeWork as potentially requiring additional liquidity, which could include and go beyond the financing commitment by SoftBank.

A better-case scenario by Fitch estimates WeWork's cash burn rate at about $900 million in 2021 and a "moderately positive free cash flow" level in 2022.

So the question is how to do you sell shared space at a time when people are still hesitant to return to the office? And what does the does the road to profitability look like for WeWork?

On CNBC-TV18’s Young Turks, India’s longest-running show on startups and entrepreneurship, Shereen Bhan spoke to Sandeep Mathrani, CEO of WeWork Global and the man steering one of the company's biggest markets, Karan Virwani, CEO of WeWork India.

Watch video for the full interview.

First Published:Oct 29, 2020 1:38 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Copyright 2023-2026 - www.financetom.com All Rights Reserved